Compound profile
Survodutide
Stronger clinical signalAlso known as: BI 456906 · glucagon/GLP-1 dual agonist
A Boehringer Ingelheim glucagon-receptor/GLP-1-receptor dual agonist in late-stage development for obesity and MASH (fatty liver disease). Part of the current wave of multi-receptor peptides competing with tirzepatide and retatrutide for the metabolic-peptide spotlight.
Overview
Survodutide is a synthetic peptide engineered to activate two hormone receptors at once, the glucagon receptor and the GLP-1 receptor, in a single molecule. Boehringer Ingelheim developed it, working from a glucagon peptide backbone rather than a GLP-1 backbone, and it carries the laboratory code BI 456906 in earlier scientific literature.
Structurally it is a 29 amino acid peptide built by swapping specific positions in the native glucagon sequence for residues from GLP-1 and from exendin-4 (the lizard derived peptide that inspired exenatide), along with one unnatural amino acid substitution to improve stability. A lysine side chain near the middle of the sequence is attached to a C18 fatty acid, the same half life extending strategy used in tirzepatide and semaglutide, which allows once weekly subcutaneous dosing.
Survodutide is being developed for two separate indications, obesity and metabolic dysfunction associated steatohepatitis, commonly called MASH, a form of progressive fatty liver disease. It holds FDA breakthrough therapy designation for MASH with moderate to advanced fibrosis, a status meant to speed development for conditions with unmet medical need, but breakthrough designation is not the same as approval. As of this review it remains an investigational drug, not marketed or approved anywhere, with results from its phase 3 SYNCHRONIZE program in obesity beginning to read out.
Mechanism (plain language)
Engages both the glucagon receptor and the GLP-1 receptor. The glucagon component is proposed to add hepatic lipid metabolism and energy-expenditure effects on top of GLP-1's appetite and glycemic effects.
How it works
Glucagon and GLP-1 are both gut and pancreas derived hormones that act on energy metabolism, but in different directions in some respects. GLP-1 slows gastric emptying, promotes glucose dependent insulin release, and increases satiety, the same pathway targeted by semaglutide. Glucagon, by contrast, is best known for raising blood sugar during fasting by triggering the liver to release stored glucose, but it also increases energy expenditure and influences how the liver handles fat, effects that are separate from its blood sugar raising role.
Survodutide is designed to engage both receptors at once but not equally. Preclinical pharmacology describes full activation of the GLP-1 receptor at expected therapeutic doses, paired with only partial activation of the glucagon receptor, a balance researchers believe is enough to add the glucagon receptor's energy expenditure and hepatic fat effects without overwhelming the blood sugar lowering benefit of GLP-1 activation. In the liver specifically, glucagon receptor activation is thought to reduce fat accumulation, which is the biological rationale for testing survodutide in MASH, a disease defined by excess fat and inflammation in liver tissue, separately from its obesity program.
What research suggests
A phase 2 dose-finding trial in adults with obesity reported dose-dependent weight loss (up to roughly 15% at the highest dose over 46 weeks versus placebo). A subsequent phase 3 trial (SYNCHRONIZE-1) reported significantly greater weight reduction than placebo at 76 weeks.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Weight reduction
A phase 2 dose finding trial in adults with obesity reported weight loss of up to roughly 15 percent at the highest dose over 46 weeks versus placebo, and a phase 3 trial (SYNCHRONIZE-1) reported weight loss up to about 16.6 percent at 76 weeks versus placebo.
Liver fat and MASH related outcomes
Trials in people with metabolic dysfunction associated steatohepatitis and liver fibrosis report reductions in liver fat and improvements in disease activity measures, supporting the drug's breakthrough therapy designation for MASH.
Glycemic control in type 2 diabetes
Dose response studies in people with type 2 diabetes report reductions in HbA1c alongside weight loss, compared with placebo and with open label semaglutide.
Energy expenditure signal
Preclinical and early clinical pharmacology work attributes part of survodutide's effect to increased energy expenditure from glucagon receptor activation, on top of the appetite reducing effect of GLP-1 receptor activation.
Uncertainties & risks
Still investigational as of last review; not an approved consumer product. Gastrointestinal adverse events are the most common side effect across trials. Comparative long-term safety versus approved incretin therapies is not yet established.
Survodutide remains an investigational drug. It is not FDA approved or approved by any other major regulator, and breakthrough therapy designation, while a meaningful regulatory signal, only speeds up the review process rather than confirming safety or effectiveness ahead of a full evaluation. Anyone outside a clinical trial encountering survodutide is dealing with an unapproved research compound. Gastrointestinal adverse events, nausea, vomiting, diarrhea, and decreased appetite, are the most commonly reported side effects across its trials, consistent with other drugs that engage the GLP-1 receptor, and they appear more often at higher doses. Because glucagon receptor activation can theoretically raise blood glucose or heart rate even as GLP-1 activation pulls in the opposite direction, the net cardiometabolic safety profile of dual agonism is still being characterized in ongoing cardiovascular outcomes trials. Long term safety data, and any comparison against approved single or dual incretin therapies like tirzepatide, will depend on trials that have not yet fully reported.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.